These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18762681)

  • 1. Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention.
    Díez JG
    J Invasive Cardiol; 2008 Sep; 20(9):482-9. PubMed ID: 18762681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    Montalescot G; White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    N Engl J Med; 2006 Sep; 355(10):1006-17. PubMed ID: 16957147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
    Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.
    Gallo R; Steinhubl SR; White HD; Montalescot G;
    Catheter Cardiovasc Interv; 2009 Feb; 73(3):319-25. PubMed ID: 19213086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin in elective percutaneous coronary intervention.
    Pasceri V
    N Engl J Med; 2006 Dec; 355(26):2789; author reply 2790-1. PubMed ID: 17195306
    [No Abstract]   [Full Text] [Related]  

  • 9. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
    Montalescot G; Gallo R; White HD; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1083-91. PubMed ID: 19926048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enoxaparin in elective percutaneous coronary intervention.
    Hamon M; Riddell JW
    N Engl J Med; 2006 Dec; 355(26):2788-9; author reply 2790-1. PubMed ID: 17195309
    [No Abstract]   [Full Text] [Related]  

  • 11. Enoxaparin in elective percutaneous coronary intervention.
    Karthikeyan G
    N Engl J Med; 2006 Dec; 355(26):2789; author reply 2790-1. PubMed ID: 17195310
    [No Abstract]   [Full Text] [Related]  

  • 12. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
    J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of anticoagulants in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: a potential role for enoxaparin.
    Christy GW
    J Invasive Cardiol; 2008 Nov; 20(11):615-21. PubMed ID: 18987403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxaparin in elective percutaneous coronary intervention.
    Schuler J; Altenberger J; Heigert M
    N Engl J Med; 2006 Dec; 355(26):2789-90; author reply 2790-1. PubMed ID: 17193723
    [No Abstract]   [Full Text] [Related]  

  • 15. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
    Lopes RD; Alexander KP; Marcucci G; White HD; Spinler S; Col J; Aylward PE; Califf RM; Mahaffey KW
    Eur Heart J; 2008 Aug; 29(15):1827-33. PubMed ID: 18519426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention.
    Marmur JD; Bullock-Palmer RP; Poludasu S; Cavusoglu E
    J Invasive Cardiol; 2009 Dec; 21(12):653-64. PubMed ID: 19966370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enoxaparin in elective percutaneous coronary intervention.
    Bhala N
    N Engl J Med; 2006 Dec; 355(26):2788; author reply 2790-1. PubMed ID: 17192548
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of bleeding after elective percutaneous coronary intervention.
    O'Neill WW
    N Engl J Med; 2006 Sep; 355(10):1058-60. PubMed ID: 16957154
    [No Abstract]   [Full Text] [Related]  

  • 20. Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes?
    Wolak A; Ayzenberg Y; Cafri C; Gilutz H; Ilia R; Zahger D
    Int J Cardiol; 2004 Aug; 96(2):151-5. PubMed ID: 15262028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.